ETNB - NASDAQ
89bio, Inc.
$14.84
+0.0000%89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
At a Glance
Live Snapshot89bio, Inc. Management Team
Mr. Rohan Palekar
Chief Executive Officer & Director
Compensation
$999,834
Mr. Ryan Stephen Martins
Chief Financial Officer
Compensation
$646,525
Dr. Harry Mansbach M.D.
Chief Medical Officer
Compensation
$717,383
Mr. Francis W. Sarena
Chief Operating Officer
Compensation
$590,473
Mr. Quoc Le-Nguyen
Chief Technical Officer
Compensation
$693,099
Mr. Michael Baldwin
Senior Vice President & Head of Quality
Ms. Melissa Abel
Senior Vice President of Commercial Strategy
Mr. Shiva K. Natarajan CPA
Senior Vice President of Finance & Principal Accounting Officer
Ms. Annie J. Chang M.B.A.
Vice President of Investor Relations & Corporate Communications
Ms. Amanda Kurihara
Vice President of People & Culture
89bio, Inc. Insider Positioning
During the last 12 months, insiders have sold $4.98M worth of ETNB shares, with no buying activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
335.4K
4.86M
-4.9M
-$4.86M
9-12 Months
0
0.00
10.5K
115.28K
-115K
-$115K
Top Buyers
No buying activity
Top Sellers
Ra Capital Management, L.P.
Director, 10 Percent Owner:
$4.86M
Le-Nguyen Quoc
Officer: See Remarks
$115K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $4.98M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
2 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
ETNB - Filing history and reports
No SEC filings available for ETNB
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.